LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

Home・Aktien・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Open

2.07 -0.48

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.02

Max

2.16

Schlüsselkennzahlen
By Trading Economics
KGV Branchendurchschnitt	1.381 35.664
EPS	-0.43
Angestellte	8

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.3M 12M
Vorheriger Eröffnungskurs	2.55
Vorheriger Schlusskurs	2.07

Minerva Neurosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Sept. 2025, 22:39 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. Sept. 2025, 16:43 UTC

Wichtige Markttreiber

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. Sept. 2025, 16:42 UTC

Wichtige Markttreiber

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. Sept. 2025, 16:35 UTC

Wichtige Markttreiber

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. Sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. Sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. Sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. Sept. 2025, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Expects Commercial Launch in 2029

15. Sept. 2025, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. Sept. 2025, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. Sept. 2025, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. Sept. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. Sept. 2025, 21:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. Sept. 2025, 21:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. Sept. 2025, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. Sept. 2025, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. Sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. Sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. Sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. Sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. Sept. 2025, 17:50 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. Sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. Sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. Sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Sept. 2025, 16:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Minerva Neurosciences Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Minerva Neurosciences Inc – Dist abgegeben haben.

Finanzen

Über Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.